Turning enzymes ON with small molecules.
暂无分享,去创建一个
[1] L. Kifle,et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. , 2006, Cell metabolism.
[2] Jonathan V. Almaden,et al. Glucose modulation of glucokinase activation by small molecules , 2008, Biochemistry.
[3] Lawrence Shapiro,et al. Crystal Structures of the Adenylate Sensor from Fission Yeast AMP-Activated Protein Kinase , 2007, Science.
[4] B. Kemp,et al. Functional Domains of the α1 Catalytic Subunit of the AMP-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.
[5] Peter J. Alaimo,et al. Chemical genetic approaches for the elucidation of signaling pathways. , 2001, Current opinion in chemical biology.
[6] K. Procházková,et al. Structure-Function Analysis of Inositol Hexakisphosphate-induced Autoprocessing of the Vibrio cholerae Multifunctional Autoprocessing RTX Toxin* , 2008, Journal of Biological Chemistry.
[7] David Carling,et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase , 2007, Nature.
[8] A. Cornish-Bowden,et al. Characteristics necessary for an interconvertible enzyme cascade to generate a highly sensitive response to an effector. , 1989, The Biochemical journal.
[9] D. Mochly‐Rosen,et al. Rationally designed peptide regulators of protein kinase C , 2009, Trends in Endocrinology & Metabolism.
[10] Venkataraman Thanabal,et al. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1♦ , 2010, The Journal of Biological Chemistry.
[11] D. Hardie. Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0982 Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status , 2022 .
[12] S. Fields,et al. Substrate-specific Activation of Sirtuins by Resveratrol* , 2005, Journal of Biological Chemistry.
[13] Brian C. Smith,et al. Mechanisms and molecular probes of sirtuins. , 2008, Chemistry & biology.
[14] Amy V. Lynch,et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.
[15] Ricardo M Biondi,et al. Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. , 2004, Trends in biochemical sciences.
[16] J. Qin,et al. Negative regulation of the deacetylase SIRT1 by DBC1 , 2008, Nature.
[17] R. Heath,et al. Defining the Mechanism of Activation of AMP-activated Protein Kinase by the Small Molecule A-769662, a Member of the Thienopyridone Family* , 2007, Journal of Biological Chemistry.
[18] Susan S. Taylor,et al. PKA-I Holoenzyme Structure Reveals a Mechanism for cAMP-Dependent Activation , 2007, Cell.
[19] S. Hawley,et al. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.
[20] Susan S. Taylor,et al. Signaling through cAMP and cAMP-dependent protein kinase: diverse strategies for drug design. , 2008, Biochimica et biophysica acta.
[21] A. Chamberlin,et al. Activation of protein phosphatase 1 by a small molecule designed to bind to the enzyme's regulatory site. , 2008, Chemistry & biology.
[22] Tapas K. Kundu,et al. Small Molecule Modulators of Histone Acetyltransferase p300* , 2003, Journal of Biological Chemistry.
[23] M. Pal. Recent advances in glucokinase activators for the treatment of type 2 diabetes. , 2009, Drug discovery today.
[24] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[25] John Kuriyan,et al. Protein-protein interactions in the allosteric regulation of protein kinases. , 2006, Current opinion in structural biology.
[26] D. Mochly‐Rosen,et al. Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. , 1999, Pharmacological research.
[27] B. Kemp,et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. , 2008, Chemistry & biology.
[28] S. Tenzer,et al. Autocatalytic cleavage of Clostridium difficile toxin B , 2007, Nature.
[29] Junjie Chen,et al. DBC1 is a negative regulator of SIRT1 , 2008, Nature.
[30] Anthony C. Bishop,et al. Brought to life: targeted activation of enzyme function with small molecules , 2009, Journal of chemical biology.
[31] M. Disatnik,et al. Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart , 2008, Science.
[32] J. Grippo,et al. Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.
[33] M. McVey,et al. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. , 1999, Genes & development.
[34] Susan S. Taylor,et al. Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A. , 2006, Analytical chemistry.
[35] K. Christopher Garcia,et al. Mechanistic and structural insights into the proteolytic activation of Vibrio cholera MARTX toxin , 2009, Nature chemical biology.
[36] P. Hergenrother,et al. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. , 2009, Journal of molecular biology.
[37] D. Hardie,et al. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.
[38] R. Hartmann,et al. 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds. , 2009, Journal of medicinal chemistry.
[39] D. Sinclair,et al. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae , 2003, Nature.
[40] R. Silverman. Implications for RNase L in prostate cancer biology. , 2003, Biochemistry.
[41] C. Herrmann,et al. Autocatalytic Processing of Clostridium difficile Toxin B , 2009, Journal of Biological Chemistry.
[42] D. Schmoll,et al. Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory Protein , 2008, Journal of Biological Chemistry.
[43] P. Hergenrother,et al. Reply to 'Small molecules not direct activators of caspases' , 2007, Nature Chemical Biology.
[44] A. Cornish-Bowden,et al. Evolution and regulatory role of the hexokinases. , 1998, Biochimica et biophysica acta.
[45] Emad S. Alnemri,et al. Crystal Structure of a Procaspase-7 Zymogen Mechanisms of Activation and Substrate Binding , 2001, Cell.
[46] Stefan Zeuzem,et al. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds , 2006, The EMBO journal.
[47] S. Sidhu,et al. Two-state selection of conformation-specific antibodies , 2009, Proceedings of the National Academy of Sciences.
[48] Benjamin F. Cravatt,et al. Chemical strategies for the global analysis of protein function. , 2000 .
[49] F. Matschinsky,et al. Assessing the potential of glucokinase activators in diabetes therapy , 2009, Nature Reviews Drug Discovery.
[50] Susan S. Taylor,et al. Contribution of Non-catalytic Core Residues to Activity and Regulation in Protein Kinase A* , 2009, Journal of Biological Chemistry.
[51] Brian K. Kennedy,et al. Sirtuins in Aging and Age-Related Disease , 2006, Cell.
[52] M. Gu,et al. Small Molecule Antagonizes Autoinhibition and Activates AMP-activated Protein Kinase in Cells* , 2008, Journal of Biological Chemistry.
[53] Chao Zhang,et al. Inhibitor Hijacking of Akt Activation , 2009, Nature chemical biology.
[54] J. Skehel,et al. Interferon action—sequence specificity of the ppp(A2′p)nA-dependent ribonuclease , 1981, Nature.
[55] C. Deng,et al. Recent progress in the biology and physiology of sirtuins , 2009, Nature.
[56] Zhi-Xin Wang,et al. Structural insight into the autoinhibition mechanism of AMP-activated protein kinase , 2009, Nature.
[57] K. Garcia,et al. Small Molecule-Induced Allosteric Activation of the Vibrio cholerae RTX Cysteine Protease Domain , 2008, Science.
[58] G. Salvesen,et al. Structural basis for the activation of human procaspase-7 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[59] E. Holmes,et al. The enzymatic synthesis of 5-amino-4-imidazolecarboxamide riboside triphosphate (ZTP). , 1984, Science.
[60] Maria Deak,et al. A phosphoserine/threonine‐binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation , 2002, The EMBO journal.
[61] A. Hattersley,et al. Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[62] D. Hardie,et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. , 2005, Cell metabolism.
[63] D. Hardie,et al. AMP-activated protein kinase as a drug target. , 2007, Annual review of pharmacology and toxicology.
[64] M. Veiga-da-Cunha,et al. Glucokinase regulatory protein is essential for the proper subcellular localisation of liver glucokinase , 1999, FEBS letters.
[65] Maria Deak,et al. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C‐terminal residues of PKA , 2000, The EMBO journal.
[66] P. Defossez,et al. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. , 2000, Science.
[67] Phuong Chung,et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.
[68] L. Kifle,et al. Discovery and SAR development of thienopyridones: a class of small molecule AMPK activators. , 2007, Bioorganic & medicinal chemistry letters.
[69] Klaus Aktories,et al. Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity* , 2007, Journal of Biological Chemistry.
[70] S H Kaufmann,et al. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. , 1999, Annual review of biochemistry.
[71] Teruyuki Nishimura,et al. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. , 2004, Structure.
[72] A. Cornish-Bowden,et al. Response coefficients of interconvertible enzyme cascades towards effectors that act on one or both modifier enzymes. , 1992, European journal of biochemistry.
[73] Y. Kitade,et al. 2‐5A induces a conformational change in the ankyrin‐repeat domain of RNase L , 2005, Proteins.
[74] Timothy B. Stockwell,et al. The Sequence of the Human Genome , 2001, Science.
[75] J. Wells,et al. A common allosteric site and mechanism in caspases , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[76] G. Salvesen,et al. Human Caspases: Activation, Specificity, and Regulation* , 2009, The Journal of Biological Chemistry.
[77] Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. , 2007, Molecular cell.
[78] D E Koshland,et al. Sensitivity amplification in biochemical systems , 1982, Quarterly Reviews of Biophysics.
[79] Liang Tong,et al. Crystal structure of the heterotrimer core of Saccharomyces cerevisiae AMPK homologue SNF1 , 2007, Nature.
[80] Chao Zhang,et al. Bypassing a Kinase Activity with an ATP-Competitive Drug , 2003, Science.
[81] M. Magnuson,et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. , 2006, Diabetes.
[82] Christopher I. Bayly,et al. Maintenance of caspase-3 proenzyme dormancy by an intrinsic “safety catch” regulatory tripeptide , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[83] D. Mochly‐Rosen,et al. Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic. , 2007, Biochemical Society transactions.
[84] D. Haussler,et al. A physical map of the human genome , 2001, Nature.
[85] P. Hergenrother,et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy , 2006, Nature chemical biology.
[86] G. Minasov,et al. Structural and Molecular Mechanism for Autoprocessing of MARTX Toxin of Vibrio cholerae at Multiple Sites* , 2009, The Journal of Biological Chemistry.
[87] J. Wells,et al. Discovery of an allosteric site in the caspases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[88] Maria Deak,et al. The PIF‐binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB , 2001, The EMBO journal.
[89] B. Viollet,et al. Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase* , 2007, Journal of Biological Chemistry.
[90] Jennifer L. Harris,et al. Small molecules not direct activators of caspases , 2007, Nature Chemical Biology.
[91] Y. Kitade,et al. Structural basis for recognition of 2′,5′‐linked oligoadenylates by human ribonuclease L , 2004, The EMBO journal.
[92] G. Salvesen,et al. Caspases - controlling intracellular signals by protease zymogen activation. , 2000, Biochimica et biophysica acta.
[93] J. Denu,et al. The Sirtuin family: therapeutic targets to treat diseases of aging. , 2008, Current opinion in chemical biology.
[94] Myriam Gorospe,et al. Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.
[95] James A. Wells,et al. Small-Molecule Activators of a Proenzyme , 2009, Science.
[96] Y. Kitade,et al. Functional Characterization of 2′,5′-Linked Oligoadenylate Binding Determinant of Human RNase L* , 2005, Journal of Biological Chemistry.
[97] M. Veiga-da-Cunha,et al. Identification of Fructose 6-Phosphate- and Fructose 1-Phosphate-binding Residues in the Regulatory Protein of Glucokinase* , 2002, The Journal of Biological Chemistry.
[98] David Loegering,et al. Components of the Cell Death Machine and Drug Sensitivity of the National Cancer Institute Cell Line Panel , 2004, Clinical Cancer Research.
[99] Junying Yuan,et al. The Jekyll and Hyde functions of caspases. , 2009, Developmental cell.
[100] P. Elliott,et al. Sirtuins — novel therapeutic targets to treat age-associated diseases , 2008, Nature Reviews Drug Discovery.
[101] Gaochao Zhou,et al. AMPK: an emerging drug target for diabetes and the metabolic syndrome. , 2009, Cell metabolism.
[102] R. Silverman,et al. Small-molecule activators of RNase L with broad-spectrum antiviral activity , 2007, Proceedings of the National Academy of Sciences.
[103] D. Hirschberg,et al. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. , 2009, Nature chemical biology.
[104] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[105] B. Stockwell. Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.
[106] J. Grimsby,et al. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. , 2006, Current medicinal chemistry.
[107] Matt Kaeberlein,et al. Sir2-Independent Life Span Extension by Calorie Restriction in Yeast , 2004, PLoS biology.
[108] Helen Conroy,et al. Caspase‐activation pathways in apoptosis and immunity , 2003, Immunological reviews.
[109] David Komander,et al. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site , 2002, The EMBO journal.